=
Note: Conversion is based on the latest values and formulas.
SMC guides and reports - Scottish Medicines Consortium Declarations of interest for SMC are aligned with Healthcare Improvement Scotland Evidence Directorate policies. Click the link to view the definitions and policies.
SMC | Scottish Medicines Consortium Register for a meeting All our SMC Committee meetings are held in public. Find out more and register your interest in attending.
tirzepatide (Mounjaro) - Scottish Medicines Consortium tirzepatide (Mounjaro) SMC ID: SMC2633 Indication: For treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet and exercise as monotherapy when …
Ultra-orphan medicines for extremely rare conditions SMC will use a broad framework to appraise ultra-orphan medicines which takes account of the nature of the condition, impact of the medicine, value for money, impact beyond direct benefits …
trastuzumab (Herceptin) - Scottish Medicines Consortium SMC ID: 928/13 Indication: Treatment of adult patients with HER2 positive metastatic breast cancer (MBC) and early breast cancer (EBC) in a range of settings (full details of licensed …
ribociclib (Kisqali) - Scottish Medicines Consortium SMC ID: SMC2198 Indication: For the treatment of women with hormone receptor (HR) positive, human epidermal growth factor receptor 2 (HER2) negative locally advanced or metastatic …
buprenorphine (Buvidal) - Scottish Medicines Consortium Indication under review: Treatment of opioid dependence within a framework of medical, social and psychological treatment. Treatment is intended for use in adults and adolescents aged 16 …
Latest update - Scottish Medicines Consortium 7 Apr 2025 · SMC publishes an updated Collaborative Advice Document for COVID-19 medicines; update to the recommendations for nirmatrelvir plus ritonavir (update to TA878) 16 April 2025
semaglutide (Ozempic) - Scottish Medicines Consortium Medicine details Medicine name: semaglutide (Ozempic) SMC ID: SMC2092 Indication: Treatment of adults with insufficiently controlled type 2 diabetes mellitus as an adjunct to diet …
How we decide - Scottish Medicines Consortium The SMC Committee takes a range of factors into consideration when deciding whether to accept a new medicine under review. The committee considers the clinical and health economic …